Login Register Cart 0
Generic placeholder image

Clinical Cancer Drugs

Editor-in-Chief

ISSN (Print): 2212-697X
ISSN (Online): 2212-6988

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

COVID-19 Related Publications Focusing on Cancer: Systematic Review of a Delicate Balance

Author(s): Mahdi F. Naimi, Maira Khan, Mary Mahler and Urban Emmenegger*

Volume 8, Issue 1, 2021

Published on: 31 December, 2020

Article ID: e301221189765 Pages: 4

DOI: 10.2174/2212697X07999201231200429

Price: $65

Abstract

Background: The ongoing COVID-19 pandemic has forced oncologists to alter their daily practice, despite the lack of substantial evidence, in order to reduce the risk of transmission among patients with underlying malignant and other concurrent medical conditions.

Objective: This systematic review compares the characteristics of oncology-focused COVID-19 manuscripts published from January 1st to April 30th, 2020, and from September 1st to September 30th, 2020, to identify the variation of publications between the start of the pandemic and our current state.

Methods: The PubMed database was searched on two different occasions using the search string “Cancer OR Tumor” AND “COVID-19 OR SARS-CoV-2”. All manuscripts pertaining to COVID-19 and oncological topics were included in this review.

Results: The search from January 1st to April 30th, 2020 and from September 1st to September 30th, 2020, resulted in 299 and 249 articles pertaining to our objective, respectively. Comparing the earlier with later publication period, the proportion of articles containing original data increased from 22.4% to 44.2%, whereas the proportion of Editorials/Correspondences decreased from 43.5% to 20.5%. Cancer patient management guidelines accounted for the majority of publications during both periods (59.2% versus 43.4%, respectively).

Conclusion: The study revealed a rapidly increasing number of COVID-19 and oncological-focused publications throughout the pandemic thus far. Given the unprecedented nature of the COVID-19 pandemic, future analyses are expected to reveal rapidly evolving publication patterns.

Keywords: Cancer, tumor, oncology, COVID-19, SARS-CoV-2, pandemic.

[1]
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21(3): 335-7.
[http://dx.doi.org/10.1016/S1470-2045(20)30096-6] [PMID: 32066541]
[2]
Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol 2020; 150: 102972.
[http://dx.doi.org/10.1016/j.critrevonc.2020.102972] [PMID: 32344317]
[3]
Cannistra SA, Haffty BG, Ballman K. Challenges faced by medical journals during the COVID-19 pandemic. J Clin Oncol 2020; 38(19): 2206-7.
[http://dx.doi.org/10.1200/JCO.20.00858] [PMID: 32267782]
[4]
Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the covid-19 pandemic: Agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020; 18(4): 366-9.
[http://dx.doi.org/10.6004/jnccn.2020.7560] [PMID: 32197238]
[5]
Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: An international collaborative group. Oncologist 2020; 25(6): e936-45.
[http://dx.doi.org/10.1634/theoncologist.2020-0213] [PMID: 32243668]
[6]
Han E, Tan MMJ, Turk E, et al. Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in asia pacific and Europe. Lancet 2020; 396(10261): 1525-34.
[http://dx.doi.org/10.1016/S0140-6736(20)32007-9] [PMID: 32979936]
[7]
Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19 Antibody Tests - At What Cost? N Engl J Med 2020; 383(6): e37.
[http://dx.doi.org/10.1056/NEJMp2017739] [PMID: 32501664]

Rights & Permissions Print Cite
Article Metrics
11
1
© 2024 Bentham Science Publishers | Privacy Policy